Strategic Partnerships Immune-Onc collaborates with BeiGene for combination trials in China, indicating openness to co-development and MSD/PD-1 pathway collaborations. This suggests downstream sales opportunities through partnered programs, licensing conversations, or co-development discussions with Asia-focused pharma.

Clinical Progress Multiple assets are in early to mid-stage trials (IO-108 in Phase 1b/2; IO-202 in Phase 1b; IO-106 and IO-312 in development), signaling ongoing clinical milestones that can attract CRO partnerships, contract research services, or investigator-initiated studies to support trial execution.

Untapped Markets Pipeline targets LILRB family including LILRB2 and LILRB4 with potential applicability across solid tumors and hematologic malignancies, presenting opportunities for diagnostic collaboration, companion diagnostics development, or targeted therapy partnerships in oncology.

Funding Readiness Recent Series B extension and ongoing private financing plus strategic board additions indicate strong funding runway, making the company a favorable candidate for advisory services, capital markets support, or strategic investment discussions.

Clinical Ecosystem Engagement with major industry players and annual meeting participation (ASH) reflects active industry integration; sales opportunities exist in clinical trial supply, manufacturing partnerships, and access to established hematology and oncology networks.